NCT06365853 2026-03-25
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie
Phase 2 Recruiting
Clinical Trials
4 trialsNCT04327999 2024-01-18
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT02818816 2018-09-27
IOPsTBURG
University Health Network, Toronto
Phase 4 Completed
NCT00824811 2012-08-02
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
M.D. Anderson Cancer Center
Phase 2 Withdrawn